Dopamine Receptor D1 Agonism and Antagonism Using a Field-Effect Transistor Assay

ACS Nano. 2017 Jun 27;11(6):5950-5959. doi: 10.1021/acsnano.7b01722. Epub 2017 Jun 7.

Abstract

The field-effect transistor (FET) has been used in the development of diagnostic tools for several decades, leading to high-performance biosensors. Therefore, the FET platform can provide the foundation for the next generation of analytical methods. A major role of G-protein-coupled receptors (GPCRs) is in the transfer of external signals into the cell and promoting human body functions; thus, their principle application is in the screening of new drugs. The research community uses efficient systems to screen potential GPCR drugs; nevertheless, the need to develop GPCR-conjugated analytical devices remains for next-generation new drug screening. In this study, we proposed an approach for studying receptor agonism and antagonism by combining the roles of FETs and GPCRs in a dopamine receptor D1 (DRD1)-conjugated FET system, which is a suitable substitute for conventional cell-based receptor assays. DRD1 was reconstituted and purified to mimic native binding pockets that have highly discriminative interactions with DRD1 agonists/antagonists. The real-time responses from the DRD1-nanohybrid FET were highly sensitive and selective for dopamine agonists/antagonists, and their maximal response levels were clearly different depending on their DRD1 affinities. Moreover, the equilibrium constants (K) were estimated by fitting the response levels. Each K value indicates the variation in the affinity between DRD1 and the agonists/antagonists; a greater K value corresponds to a stronger DRD1 affinity in agonism, whereas a lower K value in antagonism indicates a stronger dopamine-blocking effect.

Keywords: agonism−antagonism; agonists−antagonists; dopamine; dopamine receptor D1; equilibrium constants; field-effect transistor; nanohybrids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dopamine Agonists / pharmacology*
  • Dopamine Antagonists / pharmacology*
  • Drug Evaluation, Preclinical / instrumentation
  • Drug Evaluation, Preclinical / methods*
  • Equipment Design
  • Humans
  • Immobilized Proteins / agonists
  • Immobilized Proteins / antagonists & inhibitors
  • Immobilized Proteins / metabolism
  • Receptors, Dopamine D1 / agonists*
  • Receptors, Dopamine D1 / antagonists & inhibitors*
  • Receptors, Dopamine D1 / metabolism
  • Transistors, Electronic

Substances

  • Dopamine Agonists
  • Dopamine Antagonists
  • Immobilized Proteins
  • Receptors, Dopamine D1